Heron Therapeutics | HRTX - Equity Capital And Reserves


Heron Therapeutics reported $6.91M in Equity Capital and Reserves for its fiscal quarter ending in June of 2026.





Equity Capital And Reserves Change Date
ALKERMES USD 1.81B 57.02M Jun/2026
Alnylam Pharmaceuticals USD 1.35B 278.74M Jun/2026
Amarin USD 443.62M 5.8M Jun/2026
ANI Pharmaceuticals USD 597.21M 34.91M Jun/2026
Anika Therapeutics USD 137.28M 3.38M Jun/2026
Arrowhead Research USD 465.53M 148.45M Jun/2026
Eisai JPY 906.56B 7.57B Jun/2026
Emergent BioSolutions USD 649.3M 47.9M Dec/2023
GlaxoSmithKline GBP 17.64B 223M Jun/2026
Heron Therapeutics USD 6.91M 2.23M Jun/2026
Insmed USD 757.49M 52.64M Jun/2026
Ligand Pharmaceuticals USD 967.52M 29.81M Jun/2026
Merck USD 41.93B 3.94B Jun/2026
Nektar Therapeutics USD 576.22M 486.38M Mar/2026
Neurocrine Biosciences USD 3.69B 286.2M Jun/2026
Omeros USD -228.68M 15.13M Jun/2025
Pacira USD 671.98M 18.08M Jun/2026
Regeneron Pharmaceuticals USD 31.71B 287.8M Jun/2026
Roche Holding CHF 32.69B 1.11B Jun/2026
Sangamo BioSciences USD 19.6M 14.7M Jun/2025
Ultragenyx Pharmaceutical USD -291M 55M Jun/2026
Veracyte USD 1.39B 44M Jun/2026
Vertex Pharmaceuticals USD 20.25B 886M Jun/2026